AFTD's newsletter emailed 6x/year for people on the FTD journey that explains and provides updates on FTD research.
FTD Science Digest – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for FTD. Each year is focused on a new topic. This year’s title was “outcome measures and statistical power in FTD clinical trials,” which are important…
Meet the Researcher: Indira García-Cordero, PhD
“Over the years, I have had the privilege of meeting and working with people living with FTD and their families. Their strength and resilience have inspired me and motivated me to focus my research on this area. Through my work, I hope to give something back by improving our understanding of the disease. I am…
Meet the Researcher: Carmela Tartaglia, MD, FRCPC
Dr. Tartaglia is a cognitive behavioral neurologist and Professor at the University of Toronto and the University Health Network. She is the Executive Director of the Toronto Dementia Research Alliance and runs a research program on dementias – with a particular focus on FTD. The ultimate goal of her work is to diagnose neurodegenerative disorders…
FTD Science Digest: What happens when a Phase 3 clinical trial concludes?
You may know that a number of ongoing clinical trials are evaluating treatments with the potential to slow, or even stop, the progression of FTD. (Some of those trials are currently recruiting participants.) This includes Alector’s trial for latozinemab, which expects Phase 3 results some time in 2025. But what is a Phase 3 trial…
FTD Science Digest: Help Advance Science by Joining the Updated FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…
Meet the Researcher: Chiadi Onyike, MD, MHS
“The inspiration to focus my work on FTD care and research was my deep interest in understanding the cognitive and behavioral capacities that underpin human experience. FTD research has provided profound lessons about human agency, conduct, socialization, and language.” Dr. Onyike is a neuropsychiatrist specializing in FTD and young-onset dementias. He earned his medical degree…
Sign up to receive FTD Science Digest in your inbox six times a year!
